Vaccine value profile for schistosomiasis

Gavin Yamey, Duke Global Health Institute, Duke University, Durham, NC, United States. Electronic address: gavin.yamey@duke.edu.
Kaci Kennedy McDade, Duke Global Health Institute, Duke University, Durham, NC, United States. Electronic address: kaci.kennedy.mcdade@duke.edu.
Roy M. Anderson, Faculty of Medicine, School of Public Health, Imperial College London, London, United Kingdom. Electronic address: roy.anderson@imperial.ac.uk.
Sarah M. Bartsch, Public Health Informatics, Computational, and Operations Research and Center for Advanced Technology and Communication in Health, City University of New York Graduate School of Public Health and Health Policy, New York City, NY, United States. Electronic address: sbartsch1029@gmail.com.
Maria Elena Bottazzi, National School of Tropical Medicine, Baylor College of Medicine, Texas Children's Hospital Center for Vaccine Development, Houston, TX, United States. Electronic address: bottazzi@bcm.edu.
David Diemert, School of Medicine and Health Sciences, George Washington University, Washington, D.C., United States. Electronic address: ddiemert@gwu.edu.
Peter J. Hotez, National School of Tropical Medicine, Baylor College of Medicine, Texas Children's Hospital Center for Vaccine Development, Houston, TX, United States. Electronic address: hotez@bcm.edu.
Bruce Y. Lee, Public Health Informatics, Computational, and Operations Research and Center for Advanced Technology and Communication in Health, City University of New York Graduate School of Public Health and Health Policy, New York City, NY, United States. Electronic address: bruceleemdmba@gmail.com.
Donald McManus, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. Electronic address: Don.McManus@qimrberghofer.edu.au.
Adebayo J. Molehin, Department of Microbiology & Immunology, Midwestern University, Glendale, AZ, United States. Electronic address: amoleh@midwestern.edu.
Meta Roestenberg, Leiden University Medical Centre, Leiden, Netherlands. Electronic address: M.Roestenberg@lumc.nl.
David Rollinson, Global Schistosomiasis Alliance, London, United Kingdom. Electronic address: d.rollinson@nhm.ac.uk.
Afzal A. Siddiqui, Center for Tropical Medicine & Infectious Diseases, Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX, United States. Electronic address: Afzal.Siddiqui@ttuhsc.edu.
Miriam Tendler, Laboratory of Research and Development of Anti-Helminth Vaccines, Oswaldo Cruz Institute (Fiocruz), Rio de Janeiro, Brazil. Electronic address: tendlermiriam@gmail.com.
Joanne P. Webster, Department of Pathobiology and Population Sciences, Royal Veterinary College, University of London, United Kingdom. Electronic address: jowebster@rvc.ac.uk.
Hong You, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. Electronic address: Hong.You@qimrberghofer.edu.au.
Raphaël M. Zellweger, International Vaccine Institute, Seoul, Korea. Electronic address: raphael.zellweger@ivi.int.
Caroline Marshall, World Health Organization, Geneva, Switzerland.

Document Type

Journal Article

Publication Date

10-3-2025

Journal

Vaccine

Volume

64

DOI

10.1016/j.vaccine.2024.05.068

Keywords

Neglected tropical diseases; Parasitic infection; Schistosomiasis; Vaccine value

Abstract

Schistosomiasis is caused by parasitic flatworms (Schistosoma). The disease in humans can be caused by seven different species of Schistosoma: S. mansoni, S. japonicum, S. haematobium, S. malayensis, S. mekongi, S. guineensis and S. intercalatum, as well as by hybrids between species, including livestock schistosome species. People are infected when exposed to infested water and the parasite larvae penetrate the skin. Poor and rural communities are typically the most affected, and the general population who lives in affected areas and is exposed to contaminated water is at risk. Areas with poor access to safe water and adequate sanitation are also at heightened risk. About 236.6 million people required treatment for schistosomiasis in 2019-mostly people living in poor, rural communities, especially fishing and agricultural communities. This 'Vaccine Value Profile' (VVP) for schistosomiasis is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic, and societal value of pipeline vaccines and vaccine-like products. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships, and multi-lateral organizations. All contributors have extensive expertise on various elements of the schistosomiasis VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information.

Department

Medicine

Link to Full Text

Share

COinS